A bnormal involuntary movements, particularly levodopainduced dyskinesia (LID) and antipsychotic drug-elicited tardive dyskinesia, are among the most difficult to manage adverse effects associated with the treatment of Parkinson's disease (PD) and schizophrenia, respectively. The mechanisms underlying dyskinesias in levodopa-treated PD have been studied for decades. Over this time, there has been a gradual shift from a focus on mechanisms associated with surviving dopamine (presynaptic) neurons to changes in dopaminoceptive cells in the striatum.
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The medium spiny neurons (MSNs) of the striatum account for more than 90% of striatal neurons. Medium spiny neurons share a common morphology of medium-sized cell bodies with radially extending dendrites that are richly invested with dendritic spines, the thorny excrescences noted by Santiago Ramon y Cajal in the late 18th century. Displaying his usual brilliant ability to predict functional correlates of his structural observations, Cajal suggested that these spines were the site of interaction between presynaptic axons and their postsynaptic targets, and today it is clear that the dendritic spine is the primary site at which excitatory inputs regulate neurons.
There are two major subtypes of MSNs, defined on the basis of the dopamine receptor present on the cell, the peptide co-transmitter in these neurons, and the projection target of the cell: MSNs that express dopamine D 1 receptors, preprotachykinin messenger RNA, and project to the pars reticulata of the rodent substantia nigra (direct pathway cells), and D 2 receptor-expressing MSNs that contain preproenkephalin and innervate that globus pallidus before routing to the substantia nigra (indirect pathway cells).
In this issue, Suárez et al. (1) report that dopamine denervation of the striatum results in a loss of dendritic spines but not dendritic length or cell body size in MSNs, with levodopa treatment reversing the spine loss observed in dopamine-denervated mice. The authors used either D 1 receptor td-Tomato or D 2 receptorenhanced green fluorescent protein bacterial artificial chromosome (BAC) transgenic mice subjected to unilateral intrastriatal injections of 6-hydoxydopamine or vehicle. Two to three weeks later, the animals were started on 2 weeks of daily levodopa/ benserazide or vehicle injections, resulting in contralateral forelimb and orofacial dyskinesias and trunk dystonia. Suárez et al. There are some observations in the current study that differ from earlier reports. Suárez et al. (1) found that for the spine changes to be manifest, the extent of the dopaminergic innervation of the striatum must exceed 90%. However, in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated monkeys, in which the striatal dopamine loss is typically less extensive than seen after 6-hydoxydopamine treatment, a loss of spines occurs both in striatal territories suffering extensive dopamine depletion and less severely affected areas, although the degree of spine loss differs (3) . Similarly, postmortem studies of PD have reported a marked loss of dendritic spines in the striatum (4), despite the fact that the striatal dopamine loss (particularly in the caudate nucleus) rarely reaches 90% in idiopathic PD. To some degree Suárez et al. (1) findings that striatal dopamine loss must be nearly complete for significant spine loss to occur may reflect differences in methods of ascertaining the dopamine innervation: Suárez et al. (1) carefully used two indices of the extent of striatal dopamine loss. The duration of striatal dopaminergic denervation may also contribute to discrepant observations. In the current study, animals survived for 5 to 6 weeks, in contrast to the years or decades of striatal dopamine loss in monkeys with experimentally induced parkinsonism or patients with idiopathic PD. In postmortem studies, the length of the dendritic arbor is significantly decreased (4), in contrast to the lack of change in dendritic length in the current study. Finally, the various methods used to lesion the striatal dopamine innervation and the duration of survival may be important factors, particularly regarding local inflammatory changes.
Using single-cell reverse transcriptase polymerase chain reaction to define the phenotype of MSNs, Day et al. How do the findings of the current study and earlier data guide us in developing strategies to attenuate LID? The current study points to the D 1 receptor as critical. However, chronic treatment with D 1 agonists is likely to lead to cognitive deficits. Moreover, D 1 -containing MSNs undergo a phenotypic change after chronic levodopa treatment, expressing the dopamine D 3 as well as the D 1 receptor (6); D 3 partial agonists have been reported to attenuate LID in MPTP-lesioned monkeys (6) . The difficulties in developing a D 3 partial agonist for human use or for selectively activating D 3 receptors without concomitant activation of D 2 receptors suggest that some approach to the treatment of LID other than direct modulation of dopamine receptors is needed.
A large number of nondopaminergic strategies for pharmacologic amelioration of LID have been advanced (7), ranging from serotonergic agents to peptides. Among these, glutamatergic agents are arguably the best candidates. Single corticostriatal glutamatergic axons synapse with MSN spine heads in a one-toone ratio. However, in LID, this characteristic synaptic architecture between corticostriatal axons and MSN dendritic spines no longer holds, with multiple corticostriatal (but not thalamostriatal) glutamatergic axons synapsing onto MSN spines (8) . Thus, simple reversal of dendritic spine loss may not be a viable approach to attenuating dyskinesias. Instead, treatments that prevent or attenuate MSN dendritic spine loss in the first place may be a better strategy than directly targeting LID that has already developed. Increased intracellular calcium levels are thought to be the major mechanism contributing to MSN spine loss (5, 9) . Thus, postglutamate receptor strategies aimed at limiting the rate of increase and ultimate amount of calcium in spines by treatment with L-type voltage-gated calcium channel antagonists may be a useful strategy, preventing both spine loss and LID (5, 9) . Alternatively, metabotropic glutamate receptors type 2 and 3 agonists, which dampen glutamate release from corticostriatal axons and thereby limit the intraspinous surge in calcium, prevent and reverse dopamine denervation-elicited spine loss (10) . The side effect profiles in human studies of both dihydropyridine antagonists of L-type calcium channels and metabotropic glutamate receptors type 2 and 3 agonists have been very good, suggesting that the adverse effects that have plagued N-methyl-D-aspartate antagonist trials could be avoided in treating LID. Both approaches offer the potential advantage of minimizing spine loss if instituted early in the course of PD and preventing the development of dyskinesias. In attempts to reduce the burden of dyskinesias, an ounce of prevention may be worth more than a pound of cure.
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